Hepatitis is a viral disease that remains in the body for
longer durations and even lifetime, depending upon the viral genotype. It exists as Hepatitis A, B, C, D, E, G and H.
Hepatitis B and C are treated by interferon at variant doses in every
individual. There is a slight chance from recovery from Hepatitis B but it has
a vaccine. Hepatitis C is treatable yet chances of recurrence are strong
because it does not have a vaccine.
Interferon has a binding affinity with the cellular proteins
that in turns kills the viruses despite of their various shapes which may not
be identified otherwise. The Pharmacokinetics and Pharmacodynamics of
Interferon was studied with and without combination of ribavirin, administered
between the range of 800g – 1400g thrice a week or daily. Sustained Virologic
Response (SVR) and Rapid Virologic Response (RVR) exposure- response were
modeled using logistic regression. The author of the article Population
Pharmacokinetics and Pharmacodynamics of Albinterferon Alfa-2b in Patients
Treated for Hepatitis C Virus Genotype 2/3 has detailed review
on the genotype research and a comparison of efficacy of combined or individual
regimens.
Also, Bentham Science Publishers
has much more details on the viral hepatitis topics in their open access
journals.
No comments:
Post a Comment